SAN MATEO, CA, August 9, 2023 – PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection, early treatment selection and monitoring of cancer and other complex diseases – today announced that it has appointed Raj Garg, M.D., J.D. to its board of directors.
“Raj is a strategic and transformational healthcare leader with unique experience in delivering operational and clinical excellence,” said Philip Ma, CEO of PrognomiQ. “He also has deep understanding and expertise in the assessment and adoption of technologies from the lab into clinical practice. Additionally, Raj brings hands-on experience leading oncologists and other clinicians in the delivery of care to cancer patients as well as working with senior leadership and boards of innovative medical technology companies. I look forward to closely collaborating with him and our other board members in bringing forward our transformative tests to detect and treat cancer at the earliest stages.”
Dr. Garg was most recently CEO and President of Cancer Treatment Centers of America (CTCA), where he served cancer patients throughout the country. Since then, he has served as a board member to a variety of companies including Koning Corporation, Medocity and National Pain & Spine Centers, lending his expertise in strategy, board governance, risk management, compensation, culture and talent. Earlier in his career, he was a senior partner at McKinsey & Company where he led their biopharma and health care services practices.
“I’m excited about PrognomiQ’s innovative multi-omics approach to develop liquid biopsy tests for the early detection of cancer, which has the potential to truly transform outcomes for cancer patients,” said Dr. Garg. “The performance data they have shared in lung cancer and pancreatic cancer is impressive, particularly for early-stages of cancer. I look forward to working with their senior leadership team and Board as the company accelerates the development of its platform and pipeline of multi-omics products for the early detection of cancer.”
PrognomiQ will present its next round of scientific and clinical findings at the World Conference on Lung in September and at the American College of Chest Physicians (CHEST) in October.
Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases. PrognomiQ uses leading edge proteomics, metabolomics and genomics technologies to develop multi-omics products to improve human health. For more information, please visit www.prognomiq.com.